Literature DB >> 12421099

Influenza vaccinations: who needs them and when?

Eelko Hak1, Arno W Hoes, Theo J M Verheij.   

Abstract

Influenza vaccination programmes should aim at reducing the burden from influenza among those who need it most. The primary aim of this literature review is to identify who should receive priority in influenza vaccination programmes. Risk factors for severe post-influenza complications include immune-related factors, such as ageing or the presence of immune-suppression, respiratory tract disease, proneness to exacerbation of concomitant high-risk disease, potential adverse effects associated with long-term drug use or residence in closed communities with high transmission rate. When given annually in autumn, inactivated trivalent influenza vaccines can reduce severe complications from influenza among persons aged 65 years or older by 30-60%. Among children aged less than 7 years, notably those with asthma, the occurrence of otitis media or acute respiratory disease is reduced by 20-75% with vaccination. In addition, vaccination of residents of long-term care facilities and their personnel leads to a 42% reduction in mortality among patients. However, uncertainty remains about whether influenza vaccination can reduce complications from influenza among the large group of older children and persons of working-age with high-risk disease. To further increase the impact of prevention strategies, the development and application of clinical prediction rules to estimate absolute risks of post-influenza complications should be studied in relation to optimal vaccine delivery strategies. Furthermore, adequately powered studies should be conducted to demonstrate possible effectiveness of vaccination in reducing post-influenza complications among older children and working-age adults.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12421099     DOI: 10.2165/00003495-200262170-00001

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  64 in total

Review 1.  Prevention and treatment of influenza.

Authors:  R B Couch
Journal:  N Engl J Med       Date:  2000-12-14       Impact factor: 91.245

2.  Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group.

Authors: 
Journal:  Lancet       Date:  1998-12-12       Impact factor: 79.321

3.  Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.

Authors:  F G Hayden; A D Osterhaus; J J Treanor; D M Fleming; F Y Aoki; K G Nicholson; A M Bohnen; H M Hirst; O Keene; K Wightman
Journal:  N Engl J Med       Date:  1997-09-25       Impact factor: 91.245

4.  The health and economic benefits of influenza vaccination for healthy and at-risk persons aged 65 to 74 years.

Authors:  K L Nichol; M Goodman
Journal:  Pharmacoeconomics       Date:  1999       Impact factor: 4.981

5.  Clinical effectiveness of conventional influenza vaccination in asthmatic children.

Authors:  A J Smits; E Hak; W A B Stalman; G A van Essen; A W Hoes; Th J M Verheij
Journal:  Epidemiol Infect       Date:  2002-04       Impact factor: 2.451

6.  The Japanese experience with vaccinating schoolchildren against influenza.

Authors:  T A Reichert; N Sugaya; D S Fedson; W P Glezen; L Simonsen; M Tashiro
Journal:  N Engl J Med       Date:  2001-03-22       Impact factor: 91.245

7.  Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial.

Authors:  W F Carman; A G Elder; L A Wallace; K McAulay; A Walker; G D Murray; D J Stott
Journal:  Lancet       Date:  2000-01-08       Impact factor: 79.321

8.  Association of influenza vaccination and reduced risk of recurrent myocardial infarction.

Authors:  M Naghavi; Z Barlas; S Siadaty; S Naguib; M Madjid; W Casscells
Journal:  Circulation       Date:  2000-12-19       Impact factor: 29.690

9.  Influenza vaccination in the prevention of acute otitis media in children.

Authors:  T Heikkinen; O Ruuskanen; M Waris; T Ziegler; M Arola; P Halonen
Journal:  Am J Dis Child       Date:  1991-04

10.  What are the complications of influenza and can they be prevented? Experience from the 1989 epidemic of H3N2 influenza A in general practice.

Authors:  A M Connolly; R L Salmon; B Lervy; D H Williams
Journal:  BMJ       Date:  1993-05-29
View more
  2 in total

1.  Fatal influenza A infection with Staphylococcus aureus superinfection in a 49-year-old woman presenting as sudden death.

Authors:  M Tsokos; B Zöllner; H-H Feucht
Journal:  Int J Legal Med       Date:  2004-08-19       Impact factor: 2.686

2.  Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK.

Authors:  Beate Sander; Frederick G Hayden; Marlene Gyldmark; Louis P Garrison
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.